Vistagen Therapeutics Inc
vistagen.comVistagen Therapeutics Inc (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing drug candidates targeting anxiety and other central nervous system disorders. The company generates no product revenue, operating instead on equity financing and licensing arrangements while its pipeline advances through clinical trials toward potential FDA approval. Vistagen has a licensing and collaboration agreement with EverInsight Therapeutics Inc, indicating a partnership-based commercialization model in at least some markets. The company is subject to FDA oversight in the United States and, for any future clinical trials conducted in the United Kingdom or European Economic Area, to EU GDPR and comparable foreign regulatory requirements. As a pre-revenue clinical-stage company, Vistagen's capital structure is dependent on external financing rather than operating cash flows. Key filings reference Shawn K. Singh in a leadership capacity. The company's principal office has been associated with a lease in the Bayside Area. All data sourced from the 10-K filed June 17, 2025 (accession 0001411685-25-000041) for the fiscal year ended March 31, 2025.
Products & Services
Pipeline of drug candidates targeting central nervous system conditions, including anxiety disorders. Specific product candidate names are not detailed in the available filing excerpts. Candidates are subject to FDA approval and, potentially, approval by comparable foreign regulatory authorities.
Revenue Model
Pre-revenue clinical-stage company. No product sales as of the fiscal year ended March 31, 2025 (per 10-K filed June 17, 2025). Operations are funded through equity financing. A licensing and collaboration agreement with EverInsight Therapeutics Inc represents a potential future royalty or milestone-based revenue stream.
Customers & Markets
End market is prescription pharmaceuticals for patients with central nervous system disorders, including anxiety. Physicians and patients are the ultimate end users upon any future product approval. No commercial customers as of the 10-K filed June 17, 2025.
Geographic Exposure
Primary operations in the United States. Potential future clinical trial activity in the United Kingdom and European Economic Area, which would subject the company to EU GDPR and comparable data protection regulations, per the 10-K filed June 17, 2025.
Financial Snapshot
Loading...
